Precision BioSciences Provides Update on Allogeneic CAR T Programs and Path Forward with Its Lead PB
PBCAR0191 Achieved 100% Response Rate (ORR), 73% Complete Response (CR) Rate and 50% Durable Response Greater than Six Months Among Evaluable CAR T Relapsed SubjectsPBCAR0191 Achieved Peak CAR T Cell Expansion Matching Data from Autologous CAR T Peak Expansion in Long Term Durable RespondersPBCAR19B CAR T Cell Manuf...
United States Alex Kelly Michael Amoroso Precision Biosciences Inc American Society Of Hematology Dtil Biosciences Inc
Source: pharmiweb.com